GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES SUSTAINED VIROLOGIC RESPONSE VERSUS PEG-IFN/RIBAVIRIN IN PRIOR NON-RESPONDERS WITH GENOTYPE 1 CHRONIC HCV INFECTION

被引：0

作者：

Pockros, Paul ^{[1
]}

Jacobson, Ira ^{[2
]}

Boyer, Thomas D. ^{[3
]}

Schiff, Eugene R. ^{[4
]}

Everson, Gregory T. ^{[5
]}

Lee, William M. ^{[6
]}

Vierling, John M. ^{[7
,8
]}

Lawitz, Eric ^{[9
]}

Kugelmas, Marcelo ^{[10
,11
]}

Tsai, Naoky ^{[12
]}

Shiffman, Mitchell L. ^{[13
]}

Brown, Robert S. ^{[14
]}

Armstrong, Brian R. ^{[15
]}

Mattson, Alicia ^{[16
]}

Rodell, Timothy C. ^{[16
]}

Apelian, David ^{[16
]}

机构：

[1] Scripps Clin, La Jolla, CA 92037 USA

[2] Weill Cornell Med Coll, Ctr Study Hepatitis C, New York, NY USA

[3] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA

[4] Univ Miami, Sch Med, Ctr Liver Dis, Miami, FL USA

[5] Univ Colorado Denver, Dept Med, Aurora, CO USA

[6] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA

[7] Baylor Coll Med, Dept Med & Surg, Houston, TX 77030 USA

[8] St Lukes Episcopal Hosp, Houston, TX 77030 USA

[9] Alamo Med Res, San Antonio, TX USA

[10] PC, S Denver Gastroenterol, Englewood, CO USA

[11] Swedish Med Ctr, Ctr Dis Liver & Pancreas, Englewood, CO 80110 USA

[12] Univ Hawaii, Honolulu, HI 96822 USA

[13] Liver Inst Virginia, Newport News, VA USA

[14] Columbia Univ, Coll Phys & Surg, New York, NY USA

[15] QST Consultat, Allendale, MI USA

[16] Globelmmune, Louisville, CO USA

来源：

HEPATOLOGY | 2010年 / 52卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LB-6

引用

页码：404A / 405A

页数：2

共 50 条

[21] Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals
Shea, D. O.
Tuite, H.
Farrell, G.
Codd, M.
Mulcahy, F.
Norris, S.
Bergin, C.
JOURNAL OF VIRAL HEPATITIS, 2008, 15 (07) : 482 - 489
[22] Early prediction of response to Peg-IFNα-2a or Peg-IFNα-2b plus ribavirin in the single chronic hepatitis C patients by modeling the dynamics of infected cells
Ciccorossi, P.
Colombatto, P.
Maina, A.
Civitano, L.
Oliveri, F.
Sacco, R.
Coco, B.
Bonino, F.
Brunetto, M.
JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S26 - S27
[23] End of treatment response for PEG-IFN plus weight-based ribavirin nonresponders retreated with IFN alfacon-1+weight-based ribavirin
Leevy, CB
Ramaraju, G
Chalmers, CP
Blatt, LM
GASTROENTEROLOGY, 2004, 126 (04) : A697 - A698
[24] Pegylated interferon alfa-2b (PEG-IFN) plus ribavirin versus PEG-IFN for treatment of HIV/HCV co-infected patients (pts): An open, multicenter, randomized trial
Cargnel, A
Casella, A
Angeli, E
Gubertini, G
Orlando, G
Duca, P
GASTROENTEROLOGY, 2002, 122 (04) : A630 - A630
[25] Peg-IFN alpha2b and ribavirin in decompensated cirrhotic patients with chronic HCV infection: A controlled study
Iacobellis, A
Accadia, L
Caruso, N
Andriulli, A
HEPATOLOGY, 2005, 42 (04) : 529A - 529A
[26] Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV)
Younossi, Zobair M.
Limongi, Dolores
Stepanova, Maria
Pierobon, Mariaelena
Afendy, Arian
Mehta, Rohini
Baranova, Ancha
Liotta, Lance
Petricoin, Emanuel
JOURNAL OF PROTEOME RESEARCH, 2011, 10 (02) : 774 - 779
[27] Increasing of Ribavirin (RBV) doses improves the sustained virological response (SVR) in hepatits C virus (HCV) patients partial responders to pegylated interferon (Peg-IFN) and RBV
Conti, Fabio
Vukotic, Ranka
Lorenzini, Stefania
Riili, Anna
Cursaro, Carmela
Scuteri, Alessandra
Loggi, Elisabetta
Bernardi, Mauro
Andreone, Pietro
HEPATOLOGY, 2012, 56 : 1048A - 1049A
[28] Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin
Oze, T.
Hiramatsu, N.
Yakushijin, T.
Kurokawa, M.
Igura, T.
Mochizuki, K.
Imanaka, K.
Yamada, A.
Oshita, M.
Hagiwara, H.
Mita, E.
Ito, T.
Inui, Y.
Hijioka, T.
Tamura, S.
Yoshihara, H.
Hayashi, E.
Inoue, A.
Imai, Y.
Kato, M.
Yoshida, Y.
Tatsumi, T.
Ohkawa, K.
Kiso, S.
Kanto, T.
Kasahara, A.
Takehara, T.
Hayashi, N.
JOURNAL OF VIRAL HEPATITIS, 2009, 16 (08) : 578 - 585
[29] TREATMENT RESPONSE AND SAFETY OF PEG-IFN PLUS RIBAVIRIN THERAPY IN ELDERLY(≥65 YEARS) PATIENTS WITH CHRONIC HEPATITIS C
Kim, In Hee
Kim, Seong Hun
Kim, Sang Wook
Lee, Seung Ok
Lee, Soo Teik
Kim, Dae Ghon
HEPATOLOGY, 2011, 54 : 874A - 874A
[30] An open, multicenter, randomized trial comparing pegylated interferon alpha-2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN for treatment of HIV/HCV co-infected patients.
Cargnel, A
Angeli, E
Casella, A
Gubertini, G
Mainini, A
Orlando, G
Duca, P
HEPATOLOGY, 2002, 36 (04) : 363A - 363A

← 1 2 3 4 5 →